EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Core Insights - Verisk Analytics (NASDAQ:VRSK) is a data analytics and risk assessment company serving various industries, including insurance, energy, and financial services, known for its data-driven insights [1] - RBC Capital has set a price target of $250 for Verisk, indicating a potential price increase of approximately 20.19% from its current price of $208, despite a recent stock decline [2][6] Financial Performance - Verisk reported third-quarter revenue of $768 million, a nearly 6% increase from the same period in 2024, but below analysts' expectations of over $776 million [3] - The company's non-GAAP net income reached just under $241 million, or $1.72 per share, slightly exceeding the consensus estimate of $1.70 per share [3][6] Market Reaction - Following the mixed financial results, investor dissatisfaction led to a stock sell-off, with Verisk's stock currently priced at $212.01, reflecting a 1.93% increase [4] - Over the past year, Verisk's stock has fluctuated between a high of $322.92 and a low of $196.995, with a market capitalization of approximately $29.62 billion [5]

Sign in to access your portfolio Sign in ...

IF YOU SUFFERED A LOSS ON YOUR MOONLAKE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On September 28, 2025, MoonLake Immunotherapeutics announced disappointing Phase 3 results for its only drug candidate, sonelokimab ("SLK†), revealing that SLK failed to match the efficacy of its competitor, Union Chimique Belge's bimekizumab-bkz ("BIMZELX†). The Company had repeatedly promoted SLK's nanobody structure as supe ...

The data-analysis firm alleged that two former employees violated their non-competition agreements after leaving the company and working on a "copycat†business. ...

Market Overview - The US-China trade truce is expected to create more stability in the relationship, although it is characterized as a truce rather than a breakthrough [9][11][12] - The Federal Reserve cut rates by 0.25 percentage points, with indications that further cuts are not guaranteed [2][4] - The Dow Jones Industrial Average gained over 200 points, while the S&P 500 and Nasdaq experienced slight declines [3][4] Big Tech Earnings - Meta's shares fell by 11% after announcing increased capital expenditures for the upcoming year, exceeding the $72 billion planned for this year [6][32] - Microsoft also reported a 2.2% decline in shares despite good underlying metrics, as it ramped up spending to meet demand [7][32] - In contrast, Alphabet's shares rose by 5% due to a 15% increase in search revenue and growth in its Gemini AI platform [8][32] US-China Trade Negotiations - President Trump expressed satisfaction with the progress made in trade negotiations, focusing on issues like fentanyl tariffs and soybean purchases [9][10] - The meeting between Trump and Xi was brief, lasting only about 90 minutes, and did not address significant topics like Taiwan or Russia [13][14] - The long-term trajectory still points towards decoupling between the US and China, with both nations leveraging their positions [15][19] Corporate Earnings Insights - Meta's Q4 guidance was perceived as soft, leading to investor skepticism about its future AI investments [36][39] - Google's AI mode has seen rapid adoption, with 75 million daily active users, contributing positively to its search business [41][44] - Amazon's upcoming earnings report is anticipated to focus on AWS growth, which needs to exceed 19% to regain investor confidence [50][52] Cardinal Health Performance - Cardinal Health reported a 22% increase in quarterly revenue, driven by strong demand across all operating segments [105][106] - The company is focusing on specialty pharmaceuticals through strategic acquisitions, contributing significantly to profit growth [107][110] - The firm remains optimistic about future growth despite potential regulatory changes affecting the healthcare landscape [111][115]

Core Insights - Rogers Corporation has been upgraded to a "Buy" rating by B. Riley, with a price target increase from $85 to $105, reflecting confidence in the company's future performance [1][5] - The Q3 2025 earnings call provided insights into the company's financial health and strategic plans, emphasizing transparency and strong investor relations [2][5] Stock Performance - Currently, Rogers Corporation's stock is priced at $95.95, showing a notable increase of 14.79% or $12.36 [3][5] - The stock has experienced volatility, with a trading range between $90.66 and $98.08 on the day of reporting [3] - Over the past year, the stock reached a high of $114.05 and a low of $51.43, indicating dynamic market conditions [3] Market Capitalization and Trading Activity - Rogers Corporation's market capitalization is approximately $1.74 billion, highlighting its significant presence in the industry [4][5] - The trading volume for the stock today is 69,791 shares, suggesting active investor interest [4]

I am an avid investor with a major focus on small cap companies with experience in investing in US, Canadian, and European markets. My investment philosophy to generating great returns on the stock market revolves around identifying mispriced securities by understanding the drivers behind a company's financials, and ultimately, most often revealed by a DCF model valuation. This methodology doesn't limit an investor into rigid traditional value, dividend, or growth investing, but rather accounts for all of a ...

The past six months have marked an explosive rally for the top holdings of the iShares Russell 2000 ETF (NYSE:IWM), with all of the top 10 holdings posting triple-digit gains and capturing retail investors' attention.OKLO stock is lower today. See the real-time price action here. IWM Top Holdings RallyBloom Energy Corp. (NYSE:BE) is the top holding in the IWM and provides solid oxide fuel cells for distributed electricity and green hydrogen production. Bloom Energy stock has soared more than 615% since Apri ...

Key Takeaways S&P Global's Q3 adjusted EPS of $4.73 rose 21.6% y/y, topping estimates.Revenues grew 8.8% to $3.9B, led by 12% growth in Ratings and solid gains across segments.The company raised its 2025 EPS and revenue growth guidance after a strong quarterly showing.S&P Global Inc. (SPGI) has reported impressive third-quarter 2025 results, wherein earnings and revenues surpassed the Zacks Consensus Estimate.SPGI’s adjusted earnings per share (EPS) of $4.73 surpassed the Zacks Consensus Estimate by 7.5% an ...